Back to search

Peptide record

TPDB41195

DKE Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41195
DKE
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
GLLDLLKLLLEAAGW-NH2
Physicochemical Analysis
C78H129N17O20
RNCQHIMFPSTYV
L
1624.98
4.07
1
2
10
-1
-1.85
1.173
195.33
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
338.46
0
Residue Composition
number
2
A
0
R
0
N
1
D
0
C
1
E
0
Q
2
G
0
H
0
I
7
L
1
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 1 C: 0 E: 1 Q: 0 G: 2 H: 0 I: 0 L: 7 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
15
C78H129N17O20
1624.98
4.07
-1
-1.85
1.173
Amidation
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 2.10 ± 0 µM
Anticancer
2.10

Target

Breast Cancer
HMLER
Breast

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 1.57 ± 0.33 µM
Anticancer
1.57

Target

Breast Cancer
HMLER-shEcad
Breast

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 9.93 ± 0.25 µM
Anticancer
9.93

Target

Bone Cancer
U-2 OS
Bone

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022